GlassScriptPhysician profile
Tanya Sofia Vilchez
NPI 1487481446
$2,891.43
in general payments reported to CMS, 2019-2025
23 companies · $1,999 in 2025
The $1,999 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $892 · 2025: $1,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239 · Travel and Lodging: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,238.78 |
| Travel and Lodging | $652.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $741.26 | 2024-2025 | Venaseal |
| Astrazeneca Pharmaceuticals LP | $491.72 | 2024-2025 | Fasenra, Tezspire |
| Genzyme Corporation | $449.68 | 2024-2025 | |
| Glaxosmithkline, LLC. | $195.36 | 2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.25 | 2024-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.20 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $112.21 | 2024-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $91.48 | 2024-2025 | |
| Exact Sciences Corporation | $71.79 | 2024-2025 | Cologuard Collection Kit |
| Mallinckrodt Hospital Products INC. | $61.57 | 2024-2025 | Acthar |
| Lilly USA, LLC | $52.06 | 2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $50.05 | 2025 | Gvoke Hypopen |
| Ani Pharmaceuticals, INC. | $46.75 | 2024-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $35.89 | 2024-2025 | |
| Axsome Therapeutics, INC. | $34.38 | 2025 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $24.02 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Merck Sharp & Dohme LLC | $22.22 | 2025 | Keytruda |
| Averitas Pharma INC. | $18.52 | 2025 | Qutenza |
| Lundbeck LLC | $17.68 | 2025 | Rexulti |
| Almatica Pharma LLC | $16.97 | 2024 | Loreev Xr |
| Azurity Pharmaceuticals, INC. | $16.71 | 2025 | Edarbi |
| Amphastar Pharmaceuticals, INC. | $14.73 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.93 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Vilchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.